DDInter77 DDInter1676
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Amisulpride {u} (Compound) resembles {v} (Compound) Alizapride
Amisulpride {u} (Compound) binds {v} (Gene) HTR7
Amisulpride {u} (Compound) upregulates {v} (Gene) RGS2
Amisulpride {u} (Compound) causes {v} (Side Effect) Urticaria
Amisulpride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Amisulpride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Digoxin Immune Fab (Ovine)
Amisulpride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Amisulpride {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Amisulpride {u} may lead to a major life threatening interaction when taken with {v} Promethazine
Amisulpride {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Metoclopramide
Amisulpride (Compound) resembles Alizapride (Compound)
Amisulpride (Compound) binds HTR7 (Gene)
Amisulpride (Compound) upregulates RGS2 (Gene)
Amisulpride (Compound) causes Urticaria (Side Effect)
Amisulpride may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Digoxin Immune Fab (Ovine)
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Amisulpride may lead to a major life threatening interaction when taken with Ribociclib
Amisulpride may lead to a major life threatening interaction when taken with Promethazine
Amisulpride (Compound) resembles Metoclopramide (Compound) and Amisulpride may lead to a major life threatening interaction when taken with Metoclopramide